Vladimir Ruderman

Ben-Gurion University of the Negev, Be'er Sheva`, Southern District, Israel

Are you Vladimir Ruderman?

Claim your profile

Publications (3)29.2 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: An elevated homocysteine level is reported to be a risk factor for several diseases, including Alzheimer's and cerebrovascular disease. Recently, several studies have reported that homocysteine levels are elevated in many schizophrenic patients. Homocysteine levels can be lowered by oral folic acid, B-12, and pyridoxine. Forty-two schizophrenic patients with plasma homocysteine levels >15 micromol/L were treated with these vitamins for 3 months and placebo for 3 months in a study with a randomized, double-blind, placebo-controlled, crossover design. Homocysteine levels declined with vitamin therapy compared with placebo in all patients except for one noncompliant subject. Clinical symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale declined significantly with active treatment compared with placebo. Neuropsychological test results overall, and Wisconsin Card Sort (Categories Completed) test results in particular, were significantly better after vitamin treatment than after placebo. A subgroup of schizophrenic patients with hyperhomocysteinemia might benefit from the simple addition of B vitamins.
    Biological Psychiatry 09/2006; 60(3):265-9. DOI:10.1016/j.biopsych.2005.10.009 · 10.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Elevated plasma homocysteine has been found to be a risk factor for Alzheimer's disease as well as cerebral vascular disease, suggesting that some risk factors can accelerate or increase the severity of several CNS disease processes. The authors measured plasma homocysteine levels in patients with chronic schizophrenia in their catchment area. A one-way analysis of covariance with age and sex as covariates was performed on the total plasma homocysteine levels of 193 patients with schizophrenia compared with 762 subjects without the diagnosis of schizophrenia who were evaluated in a screening program for employee health. The effect of schizophrenia was marked: the mean homocysteine level was 16.3 micro M (SD=11.8) in patients with schizophrenia compared with 10.6 micro M (SD=3.6) in healthy comparison subjects. The difference between groups was almost entirely attributable to the homocysteine levels of young male patients with schizophrenia. Elevated levels of homocysteine in young male patients with schizophrenia could be related to the pathophysiology of aspects of this illness.
    American Journal of Psychiatry 11/2002; 159(10):1790-2. DOI:10.1176/appi.ajp.159.10.1790 · 13.56 Impact Factor
  • V. Ruderman · Z. Stahl · B.-A. Sela · R. H. Belmaker · J. Levine
    European Neuropsychopharmacology 10/2002; 12:256-257. DOI:10.1016/S0924-977X(02)80335-2 · 5.40 Impact Factor

Publication Stats

185 Citations
29.20 Total Impact Points


  • 2006
    • Ben-Gurion University of the Negev
      • Faculty of Health Sciences
      Be'er Sheva`, Southern District, Israel